In 2015, the American Heart Association’s research report stated that around 41.5% overall U.S. population was suffering some kind of cardiovascular disorder. It also forecasted that this will grow to 45% by 2035. According to the research study, changing dietary habits, consumption of junk and fast food, highly sedentary lifestyle are the key factors increasing the risk of cardiovascular diseases.

Report Overview @ 

https://www.transparencymarketresearch.com/cardiovascular-drugs-market.html

In the same year, the Center for Disease Control and Prevention (CDC) of the United States published a report that further highlighted that smoking, high cholesterol, and high blood pressure are the main culprits for causing heart diseases. Nearly half of the US population (around 47%) have at least one of these three risk factors.

Rise of cardiovascular diseases has become one of the major health-related problems across the globe. To tackle this, several leading players in the cardiovascular drugs market are investing heavily for the development of new drugs that are more efficient and have lesser side effects. It has led to a surge of opportunities for the development of the market with research analysts predicting that the global cardiovascular drug market will be worth US$91.0 billion by the end of 2025.

Request Brochure @ 

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33281

How Pipeline Drugs Spark Competition?

As mentioned before, the development of new drugs with greater efficiency and lesser side effects is imperative for market growth. Hyperlipidemia and hypertension are the main disorders that drug manufacturers are targeting. Launch of PCSK9 inhibitors in 2016 by Pfizer Inc., CETP inhibitor anacetrapib by Merck, and a new LDL lowering drug ETC 1002 by Esperion Therapeutics are some of the notable examples of the efforts taken by cardiovascular drug manufacturers to step up in the market.

However, there are some causes of concern for these drug manufacturers. One big cause of concern is the expiry of patent exclusivity of highly popular cardiovascular drugs. It has led to the spread of a large number of generic drugs in the market. A notable example is the AstraZeneca case. The company lost its hyperlipidemia treatment drug patent in early 2016 and in April 2016, the United States FDA gave its approval to Watson Pharmaceuticals Inc. to launch a generic drug.